A genetic test can sound like a glimpse into the future, especially when cancer or heart disease runs through a family. Federal prosecutors say that promise was used to steer Medicare beneficiaries into medically unnecessary testing while a fraud conspiracy generated an extraordinary volume of claims.
The $174 million was billing, not a medical breakthrough
The case centers on Spivey and co-defendant Jamie McNamara. Prosecutors said the pair conspired to submit claims for cancer genetic testing and cardiovascular genetic testing that Medicare patients did not medically need.
The patients were not receiving a useful diagnosis in return. In its July 30 enforcement announcement, the Justice Department said the testing provided no answers about predisposition to life-threatening illnesses, even as the conspiracy submitted $174 million in fraudulent Medicare claims. Spivey was sentenced for his role.
The underlying case record adds scale and method. Spivey pleaded guilty in July 2024 after prosecutors said laboratories controlled by the pair used orders obtained through telemarketers and purported telemedicine doctors who neither treated nor consulted the beneficiaries. McNamara later received a ten-year prison sentence, with more than $55 million in restitution ordered and more than $7 million forfeited.
That distinction matters. The headline figure describes claims submitted to Medicare, not a fund available to patients and not proof that the government paid every dollar. It measures how aggressively the tests were pushed through the billing system.
Free retirement updates: Scam calls targeting retirees change every week. Our free Retirement Shield newsletter flags the ones going around and the one tell that stops each. Sign up free.
A cheek swab can create a durable financial record
Genetic testing pitches often make the procedure seem harmless: answer a call, sign a form, provide a cheek swab. The financial trail is less visible. A Medicare number can support a claim submitted by a laboratory the patient has never visited, based on an order from a clinician who may not be the patient’s regular doctor.
For retirees, the immediate risk is not always a bill in the mailbox. The claim may be paid by Medicare, which means the cost is borne by the program and ultimately by taxpayers. A questionable claim can also complicate a later legitimate request if records suggest that similar testing has already been performed.
A sound medical process starts with the clinician treating the patient. Family history, symptoms and the effect of a result on treatment should drive the decision. A cold caller’s promise that Medicare will cover a test is not a substitute for that conversation.
The Medicare statement is an early-warning system
Beneficiaries receive Medicare Summary Notices for Original Medicare claims and explanations of benefits from Medicare Advantage plans. Those documents are not routine clutter. They show the provider, service and amount billed, creating a chance to spot a test that was never ordered or a supplier that is unfamiliar.
Medicare’s current fraud-reporting guidance tells beneficiaries to compare claim dates and services with their own calendars, protect the Medicare number and question incorrect charges. Suspected fraud can be reported at 1-800-MEDICARE or through HHS’s inspector general.
Reporting an unexplained claim is not accusing a personal doctor of a crime. It gives the program enough information to determine whether a coding error, identity misuse or larger billing pattern is involved. Notes should include the date of the call, the representative’s name and any confirmation number.
Consent to testing is not consent to every claim
A beneficiary may have agreed to a test without understanding who ordered it or how the laboratory would bill. That does not make an unnecessary service medically justified. Nor does it erase the value of raising questions afterward.
Families helping an older relative manage paperwork can watch for genetic-test boxes arriving after unsolicited calls, repeated requests for a Medicare card, or explanations of benefits listing laboratories in another state. The safest response is to pause and contact the treating clinician and Medicare using independently obtained numbers.
Genetic information is unusually sensitive because it can reveal information about relatives as well as the person tested. A sales pitch that minimizes privacy, refuses to identify the ordering clinician or focuses only on “free” coverage deserves more scrutiny, not less.
A legitimate test should also produce a clear path for interpreting the result. The patient should know which clinician will explain the finding, whether it changes care and how the laboratory will handle the specimen and data. Testing without that follow-through creates information without medical direction.
The prosecution puts the patient’s outcome back at the center
Large fraud cases can become a contest of numbers, but the Justice Department’s account includes the essential measure: patients were lured into tests and received no meaningful answers about the diseases used to persuade them. The billed amount was enormous; the medical value described by prosecutors was absent.
For older Americans, the protective habit is simple and concrete. Keep the Medicare number private, let a treating clinician establish medical necessity, and read every claim notice. The Spivey sentence shows why a test that feels costless at the kitchen table can be extraordinarily expensive once it enters Medicare’s payment system.
This article was researched and drafted with AI assistance and reviewed against the linked primary sources.
More Financial Reading
- Bank statements: how long to keep them and when to toss them
- How many CDs can you park at 1 bank? FDIC rules you must know
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
